Tiago Rodrigues
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Tiago Rodrigues has a total of 271 co-authors. Here are the top co-authors by number of shared publications:
- Letícia Silva Ferraz
Center for Natural and Human Sciences (CCNH), Federal University of ABC (UFABC), Santo André, SP, Brazil
12 shared publications - Débora Cristina Damasceno
Universidade Estadual Paulista
6 shared publications - Edgar Julian Paredes-Gamero
Laboratory of Molecular Biology, Federal University of Mato Grosso do Sul, Campo Grande, Mato Grosso do Sul, Brazil
5 shared publications - Gustavo Tadeu Volpato
Federal University of Mato Grosso
5 shared publications - Ivarne Luis Santos Tersariol
Departamento de Bioquímica, Universidade Federal de São Paulo, São Paulo, Brazil
5 shared publications - Laura Francisca Leite Do Prado-Souza
Federal University of ABC (UFABC)
5 shared publications
Latest Publications
- Open Access
- 14 August 2026
- Published by Elsevier in Archives of Biochemistry and Biophysics
- Vol. 785
Natural metabolites from Tabebuia aurea reveal isoform-specific and cooperative modulation of cathepsins B and L
- 14 August 2026
- Published by Elsevier in Archives of Biochemistry and Biophysics
- Vol. 785
Open AccessNatural metabolites from Tabebuia aurea reveal isoform-specific and cooperative modulation of cathepsins B and L
- Open Access
- 10 August 2026
- Published by American Chemical Society (ACS) in ACS Pharmacology & Translational Science
- Vol. 9 (9) , 2454-2468
Antiproliferation and Anti-invasion Activity of Binuclear Copper(II) Complex in BRAFi-Resistant Melanoma Cells
Melanoma lethality is driven by high intratumoral heterogeneity, metastatic competence, and phenotypic plasticity, which foster rapid emergence of resistance to targeted therapies such as BRAF inhibitors (BRAFi, e.g. vemurafenib). Copper(II) complexes have emerged as promising anticancer candidates, yet their activity against BRAFi-resistant melanoma remains poorly defined. Here, we show that the binuclear copper(II) complex [Cu2(apyhist)2dpam](ClO4)4 (herein referred to as [Cu(II)L]) displays low-micromolar cytotoxicity and antiproliferative activity in parental and BRAFi-resistant melanoma models. Binuclear [Cu(II)L] suppresses melanoma migration and invasion and reduces tumor burden and dermal invasion in a reconstructed human skin melanoma model with limited toxicity to normal tissue. Mechanistically, [Cu2(apyhist)2dpam](ClO4)4 triggers a ROS-dependent stress response that is attenuated by N-acetylcysteine, leading to DNA damage, mitochondrial depolarization and caspase-independent cell death. Molecular profiling indicates engagement of cell cycle arrest and stress-adaptation programs, with signatures suggesting ferroptotic-associated, necroptotic and autophagy-related signaling, pointing to a redox-driven, diverse mechanism rather than a single dominant death pathway. Different modulation of key markers (PARP1, H2AX, MLKL, GPX4, LC3B-II, and p62) supports that its multitarget activity can bypass adaptive resistance mechanisms. Collectively, these findings support binuclear [Cu(II)L] as a candidate to target invasive and drug-resistant melanoma phenotypes.
- 10 August 2026
- Published by American Chemical Society (ACS) in ACS Pharmacology & Translational Science
- Vol. 9 (9) , 2454-2468
Open AccessAntiproliferation and Anti-invasion Activity of Binuclear Copper(II) Complex in BRAFi-Resistant Melanoma Cells
Melanoma lethality is driven by high intratumoral heterogeneity, metastatic competence, and phenotypic plasticity, which foster rapid emergence of resistance to targeted therapies such as BRAF inhibitors (BRAFi, e.g. vemurafenib). Copper(II) complexes have emerged as promising anticancer candidates, yet their activity against BRAFi-resistant melanoma remains poorly defined. Here, we show that the binuclear copper(II) complex [Cu2(apyhist)2dpam](ClO4)4 (herein referred to as [Cu(II)L]) displays low-micromolar cytotoxicity and antiproliferative activity in parental and BRAFi-resistant melanoma models. Binuclear [Cu(II)L] suppresses melanoma migration and invasion and reduces tumor burden and dermal invasion in a reconstructed human skin melanoma model with limited toxicity to normal tissue. Mechanistically, [Cu2(apyhist)2dpam](ClO4)4 triggers a ROS-dependent stress response that is attenuated by N-acetylcysteine, leading to DNA damage, mitochondrial depolarization and caspase-independent cell death. Molecular profiling indicates engagement of cell cycle arrest and stress-adaptation programs, with signatures suggesting ferroptotic-associated, necroptotic and autophagy-related signaling, pointing to a redox-driven, diverse mechanism rather than a single dominant death pathway. Different modulation of key markers (PARP1, H2AX, MLKL, GPX4, LC3B-II, and p62) supports that its multitarget activity can bypass adaptive resistance mechanisms. Collectively, these findings support binuclear [Cu(II)L] as a candidate to target invasive and drug-resistant melanoma phenotypes.
- Open Access
- 31 July 2026
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 11 (31) , 45657-45678
Imidazo[1,2- a ]pyridines as Privileged Scaffolds: Synthetic Advances, Biological Activities, and Translational Challenges
Imidazo[1,2-a]pyridine derivatives are privileged scaffolds in medicinal chemistry due to their structural versatility, favorable physicochemical properties, and broad pharmacological relevance. Their fused heterocyclic framework enables extensive functionalization while preserving conformational rigidity and optimal heteroatom distribution, making this core highly attractive for drug discovery. This systematic review summarizes recent advances (last 5 years) in the synthesis, structural diversification, and biological evaluation of imidazo[1,2-a]pyridine-based compounds. A comprehensive literature search was performed using the Scopus and Web of Science databases, focusing on studies reporting relevant biological data. The reviewed derivatives display diverse pharmacological activities, including anticancer, antimicrobial, antitubercular, antifungal, antiparasitic, neuroactive, anti-inflammatory, antidiabetic, and ferroptosis-modulating effects. Emphasis is placed on structure–activity relationships, scaffold-hopping strategies, and emerging hybrid designs. Despite promising in vitro potency against multiple therapeutic targets, important limitations remain. Many compounds still lack in vivo validation, pharmacokinetic characterization, and ADME/Tox optimization, restricting their progression toward preclinical development. In addition, structural exploration remains concentrated on conventional substitution patterns, underscoring the need for broader bioisosteric and fragment-based approaches. Overall, this review consolidates recent advances, highlights critical knowledge gaps, and outlines future directions for the rational development of imidazo[1,2-a]pyridine-based therapeutics.
- 31 July 2026
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 11 (31) , 45657-45678
Open AccessImidazo[1,2- a ]pyridines as Privileged Scaffolds: Synthetic Advances, Biological Activities, and Translational Challenges
Imidazo[1,2-a]pyridine derivatives are privileged scaffolds in medicinal chemistry due to their structural versatility, favorable physicochemical properties, and broad pharmacological relevance. Their fused heterocyclic framework enables extensive functionalization while preserving conformational rigidity and optimal heteroatom distribution, making this core highly attractive for drug discovery. This systematic review summarizes recent advances (last 5 years) in the synthesis, structural diversification, and biological evaluation of imidazo[1,2-a]pyridine-based compounds. A comprehensive literature search was performed using the Scopus and Web of Science databases, focusing on studies reporting relevant biological data. The reviewed derivatives display diverse pharmacological activities, including anticancer, antimicrobial, antitubercular, antifungal, antiparasitic, neuroactive, anti-inflammatory, antidiabetic, and ferroptosis-modulating effects. Emphasis is placed on structure–activity relationships, scaffold-hopping strategies, and emerging hybrid designs. Despite promising in vitro potency against multiple therapeutic targets, important limitations remain. Many compounds still lack in vivo validation, pharmacokinetic characterization, and ADME/Tox optimization, restricting their progression toward preclinical development. In addition, structural exploration remains concentrated on conventional substitution patterns, underscoring the need for broader bioisosteric and fragment-based approaches. Overall, this review consolidates recent advances, highlights critical knowledge gaps, and outlines future directions for the rational development of imidazo[1,2-a]pyridine-based therapeutics.
- Open Access
- 2 July 2026
- Published by Elsevier in Biochemical Pharmacology
- Vol. 252, 118211
MAPK-driven remodeling of mitochondrial dynamics in melanoma: implications for metabolic plasticity and response to targeted therapy
- 2 July 2026
- Published by Elsevier in Biochemical Pharmacology
- Vol. 252, 118211
Open AccessMAPK-driven remodeling of mitochondrial dynamics in melanoma: implications for metabolic plasticity and response to targeted therapy
- Open Access
- 23 June 2026
- Published by Elsevier in Phytomedicine
- Vol. 159, 158488
Mitochondria-mediated apoptosis induced by acetogenins from Porcelia macrocarpa (Annonaceae) in K562 chronic myeloid leukemia cells
- 23 June 2026
- Published by Elsevier in Phytomedicine
- Vol. 159, 158488
Open AccessMitochondria-mediated apoptosis induced by acetogenins from Porcelia macrocarpa (Annonaceae) in K562 chronic myeloid leukemia cells
- Open Access
- 8 April 2026
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 817, 153748
Kunitz-type serine protease inhibitor rBmTI-6 as a potential therapeutic lead for lung adenocarcinoma
- 8 April 2026
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 817, 153748
Open AccessKunitz-type serine protease inhibitor rBmTI-6 as a potential therapeutic lead for lung adenocarcinoma
- 1 January 2026
- Published by Editora Cientifica Digital
- p. 166-187
AVALIAÇÃO MICROBIOLÓGICA E FÍSICO-QUÍMICA DE PETISCOS CANINOS FORMULADOS COM EXTRATO AQUOSO DE PRÓPOLIS
Objetivo: Avaliar, de forma preliminar, as características microbiológicas e físico-químicas de petiscos caninos contendo diferentes concentrações de própolis. Métodos: Foram desenvolvidas quatro formulações: controle (0%) e com 0,3%, 0,5% e 1,0% de própolis. Foram realizadas análises microbiológicas de aeróbios mesófilos, Enterobacteriaceae, fungos e leveduras, além de determinações de pH, umidade, cinzas, lipídios, proteínas e carboidratos. Resultados: Não houve crescimento de aeróbios mesófilos e Enterobacteriaceae. A formulação controle não apresentou crescimento em PDA, enquanto as formulações com própolis apresentaram baixas contagens de fungos e leveduras. As amostras apresentaram pH levemente ácido, baixos teores de umidade e valores semelhantes de lipídios. A formulação com 1,0% de própolis apresentou maior teor de proteínas e menor umidade. Conclusão: A incorporação de própolis às formulações de petiscos caninos foi tecnicamente viável, sem alterações negativas relevantes nos parâmetros avaliados. Entretanto, os resultados são preliminares e não permitem definir a concentração mais adequada, sendo necessários estudos complementares de estabilidade (Shelf Life), microbiologia e replicação dos ensaios.
- 1 January 2026
- Published by Editora Cientifica Digital
- p. 166-187
AVALIAÇÃO MICROBIOLÓGICA E FÍSICO-QUÍMICA DE PETISCOS CANINOS FORMULADOS COM EXTRATO AQUOSO DE PRÓPOLIS
Objetivo: Avaliar, de forma preliminar, as características microbiológicas e físico-químicas de petiscos caninos contendo diferentes concentrações de própolis. Métodos: Foram desenvolvidas quatro formulações: controle (0%) e com 0,3%, 0,5% e 1,0% de própolis. Foram realizadas análises microbiológicas de aeróbios mesófilos, Enterobacteriaceae, fungos e leveduras, além de determinações de pH, umidade, cinzas, lipídios, proteínas e carboidratos. Resultados: Não houve crescimento de aeróbios mesófilos e Enterobacteriaceae. A formulação controle não apresentou crescimento em PDA, enquanto as formulações com própolis apresentaram baixas contagens de fungos e leveduras. As amostras apresentaram pH levemente ácido, baixos teores de umidade e valores semelhantes de lipídios. A formulação com 1,0% de própolis apresentou maior teor de proteínas e menor umidade. Conclusão: A incorporação de própolis às formulações de petiscos caninos foi tecnicamente viável, sem alterações negativas relevantes nos parâmetros avaliados. Entretanto, os resultados são preliminares e não permitem definir a concentração mais adequada, sendo necessários estudos complementares de estabilidade (Shelf Life), microbiologia e replicação dos ensaios.
- Open Access
- 20 November 2025
- Published by Polish Pharmaceutical Society in Acta Poloniae Pharmaceutica - Drug Research
- Vol. 82 (3) , 495-502
Antioxidant Activity of Perphenazine
Reactive oxygen species (ROS) play a dual role in the human body; they are essential for normal cellular signaling but, when produced in excess, can disrupt metabolic processes and induce oxidative stress. The body relies on various defense mechanisms to neutralize ROS. Phenothiazine derivatives, due to their core tricyclic structure, are considered potential antioxidants. This study focused on evaluating the antioxidant capacity of perphenazine, a representative phenothiazine derivative, and comparing it to well-known antioxidants, Trolox and ascorbic acid. To achieve this, a series of spectrophotometric assays were performed: ABTS, DPPH, CUPRAC, FRAP, and superoxide anion (O2•−) scavenging. The results indicate that perphenazine shows significant antioxidant properties, particularly through its ability to reduce copper (Cu²⁺) and iron (Fe³⁺) ions and to scavenge ABTS•⁺ radicals. In contrast, its activity against DPPH• and superoxide anions was less pronounced. Relative antioxidant effectiveness, based on IC50 values, followed the order: CUPRAC > FRAP > ABTS > O2•− > DPPH. These findings suggest that perphenazine possesses selective antioxidant potential. Further studies on other phenothiazine derivatives are warranted to comprehensively assess their antioxidative potential.
- 20 November 2025
- Published by Polish Pharmaceutical Society in Acta Poloniae Pharmaceutica - Drug Research
- Vol. 82 (3) , 495-502
Open AccessAntioxidant Activity of Perphenazine
Reactive oxygen species (ROS) play a dual role in the human body; they are essential for normal cellular signaling but, when produced in excess, can disrupt metabolic processes and induce oxidative stress. The body relies on various defense mechanisms to neutralize ROS. Phenothiazine derivatives, due to their core tricyclic structure, are considered potential antioxidants. This study focused on evaluating the antioxidant capacity of perphenazine, a representative phenothiazine derivative, and comparing it to well-known antioxidants, Trolox and ascorbic acid. To achieve this, a series of spectrophotometric assays were performed: ABTS, DPPH, CUPRAC, FRAP, and superoxide anion (O2•−) scavenging. The results indicate that perphenazine shows significant antioxidant properties, particularly through its ability to reduce copper (Cu²⁺) and iron (Fe³⁺) ions and to scavenge ABTS•⁺ radicals. In contrast, its activity against DPPH• and superoxide anions was less pronounced. Relative antioxidant effectiveness, based on IC50 values, followed the order: CUPRAC > FRAP > ABTS > O2•− > DPPH. These findings suggest that perphenazine possesses selective antioxidant potential. Further studies on other phenothiazine derivatives are warranted to comprehensively assess their antioxidative potential.
- Open Access
- 20 November 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 41129
Nitric oxide modulates UDP-evoked cytosolic transients via P2Y6 purinoceptor stimulation
Glycosaminoglycans (GAGs) and proteoglycans are key components of the extracellular matrix, playing structural and regulatory roles in various biological processes. GAGs are involved in modulating endothelial nitric oxide synthase (eNOS) and nitric oxide (NO) production. CHO-745 cells, deficient in GAGs, produce significantly higher NO levels than wild-type CHO-K1 cells. Since NO is crucial for vascular function, this study investigated how NO overproduction in GAG-deficient cells affects cytosolic Ca2⁺ transients triggered by P2Y6 receptor (P2Y6R) activation with UDP, a vascular tone regulator. Results showed that GAG-deficient CHO-745 cells experience basal oxidative and nitrosative stress. Although integrin expression was similar, the RGD peptide increased NO production in CHO-K1 but not in CHO-745. P2Y6R activation involved phospholipase C and endoplasmic reticulum (ER) Ca2⁺ stores, processes dependent on surface GAGs. Additionally, store-operated Ca2⁺ entry and Na⁺/Ca2⁺ exchanger (NCX) were involved in UDP-induced Ca2⁺ responses, influenced by NO levels. Excess NO also contributed to ER stress and cell death, particularly in the absence of GAGs. Overall, GAG deficiency leads to oxidative stress, disrupted Ca2⁺ homeostasis, ER stress, and apoptosis, underscoring the importance of GAGs in purinergic signaling and vascular physiology.
- 20 November 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 41129
Open AccessNitric oxide modulates UDP-evoked cytosolic transients via P2Y6 purinoceptor stimulation
Glycosaminoglycans (GAGs) and proteoglycans are key components of the extracellular matrix, playing structural and regulatory roles in various biological processes. GAGs are involved in modulating endothelial nitric oxide synthase (eNOS) and nitric oxide (NO) production. CHO-745 cells, deficient in GAGs, produce significantly higher NO levels than wild-type CHO-K1 cells. Since NO is crucial for vascular function, this study investigated how NO overproduction in GAG-deficient cells affects cytosolic Ca2⁺ transients triggered by P2Y6 receptor (P2Y6R) activation with UDP, a vascular tone regulator. Results showed that GAG-deficient CHO-745 cells experience basal oxidative and nitrosative stress. Although integrin expression was similar, the RGD peptide increased NO production in CHO-K1 but not in CHO-745. P2Y6R activation involved phospholipase C and endoplasmic reticulum (ER) Ca2⁺ stores, processes dependent on surface GAGs. Additionally, store-operated Ca2⁺ entry and Na⁺/Ca2⁺ exchanger (NCX) were involved in UDP-induced Ca2⁺ responses, influenced by NO levels. Excess NO also contributed to ER stress and cell death, particularly in the absence of GAGs. Overall, GAG deficiency leads to oxidative stress, disrupted Ca2⁺ homeostasis, ER stress, and apoptosis, underscoring the importance of GAGs in purinergic signaling and vascular physiology.
- 1 October 2025
- Published by Springer Nature
- p. 955-973
Emerging Roles of Sodium/Calcium Exchangers in Cancer
- 1 October 2025
- Published by Springer Nature
- p. 955-973
Emerging Roles of Sodium/Calcium Exchangers in Cancer